RESUMEN
BACKGROUND:Diabetic lower limb ischemia is prone to involve distal lower limb arteries, and a conventional treatment is often unable to obtain the ideal effect. OBJECTIVE:To investigate the effect and safety of umbilical cord blood stem cel transplantation in the treatment of diabetic lower limb ischemia. METHODS: A diabetic rat model of lower limb ischemia was established, and along the femoral artery, five points were selected for injection of human umbilical cord mesenchymal stem cel suspension, 20 μL per point. At 1, 2, 4 weeks after transplantation, transcutaneous oxygen pressure, vascular density and vascular endothelial growth factor level in the ischemic region, and incidence of adverse reactions were recorded. RESULTS AND CONCLUSION:At 1, 2 and 4 weeks after transplantation, the transcutaneous oxygen pressure, vascular density and vascular endothelial growth factor level in the ischemic region were found increasing, which were significantly different from those before transplantation (P < 0.05). At different time after transplantation, al animals had no inflammatory reactions such as skin bleeding and dermatitis, and local red, sweling, hot, pain, and had no tumor-like growth in organs. These findings indicate that umbilical cord blood stem cel transplantation can safely and significantly improve symptoms of diabetic lower limb ischemia, which has certain application feasibility. Cite this article:Xie LH, Xing L, Zheng H. Feasibility of umbilical cord blood stem cel transplantation for the treatment of diabetic lower limb ischemia. Zhongguo Zuzhi Gongcheng Yanjiu. 2016;20(1):78-82.
RESUMEN
BACKGROUND:Human umbilical cord blood-derived mesenchymal stem cels are able to repair and regenerate the injured myocardium, which is a new therapy for myocardial infarctionvia transplantation. OBJECTIVE:To explore the therapeutic efficacy of intracoronary injection of human umbilical cord blood-derived mesenchymal stem cels on acute myocardial infarction in rats. METHODS:Thirty-two rats were selected to make animal models of ligation of the left anterior descending coronary, and then model rats were randomized equaly to transplantation group and model group. Human umbilical cord blood-derived mesenchymal stem cels were isolated and prepared into cel suspension. Rats in the transplantation group were subjected to transplantation of human umbilical cord blood-derived mesenchymal stem cels. RESULTS AND CONCLUSION: Human umbilical cord blood-derived mesenchymal stem cels were successfuly isolated and cultured in vitro. Compared with the model group, the microvessel density, left ventricular end-systolic pressure and ±dp/dtmax were significantly increased in the transplantation group (P < 0.05), while the left ventricular end-diastolic pressure was decreased dramaticaly (P < 0.05). Electrocardiography findings showed that the heart function of rats in the transplantation group was improved slightly. These findings indicate that human umbilical cord blood-derived mesenchymal stem cels can promote myocardial angiogenesis and improve heart function of rats with myocardial infarction.
RESUMEN
BACKGROUND:To protect the pulmonary vascular endothelial cels in the body is an important part to reduce pulmonary circulation pressure and prevent pulmonary hypertension. OBJECTIVE:To observe the therapeutic efficacy of umbilical cord blood mesenchymal stem cel transplantation carrying human telomerase reverse transcriptase (hTERT) in the treatment of pulmonary hypertension in rats. METHODS:Umbilical cord blood mesenchymal stem cels were cultured, purified and transfected with adenovirus carrying hTERT gene. Sixty Sprague-Dawley male rats were randomly divided into model group, blank adenovirus group, adenoviral delivery group, with 20 rats in each group. Then, the rats were respectively injectedvia the jugular vein with 1 mL L-DBEB, 1 mL umbilical cord blood mesenchymal stem cel suspension (1.5×1010/L), and 1 mL hTERT-transfected umbilical cord blood mesenchymal stem cel suspension (1.5×1010/L) after models of pulmonary hypertension were establishedvia intraperitoneal injection of monocrotaline. After 21 days of transplantation, hemodynamic changes, plasma endothelin 1 levels and the hypertrophy index of the right ventricle were detected. RESULTS AND CONCLUSION: There was no difference in arterial blood pressure among the three groups (P 0.05). These findings indicate that umbilical cord blood mesenchymal stem cel transplantation carrying hTERT gene can improve the hemodynamic abnormalities in the body and also protect vascular endothelial cels in the body.
RESUMEN
BACKGROUND:There are no available therapies for spinal cord ischemia-reperfusion injury, and stem cel transplantation is a focused topics. OBJECTIVE:To observe the therapeutic effect of hypoxia-inducible facotr-1α gene-modified umbilical cord blood mesenchymal stem cels (UC-MSCs) transplantedvia the infrarenal abdominal aorta on spinal cord ischemia-reperfusion injury in rats. METHODS:Thirty adult female Sprague-Dawley rats were randomly divided into three groups, with 10 rats in each group. The infrarenal abdominal aorta of rats was occluded surgicaly for 1 hour, and then the spinal cord reperfusion was restored. At 2 hours after reperfusion, 1 mL of 10% PBS, UC-MSCs suspension and hypoxia-inducible factor-1α-modified UC-MSCs suspension was injectedvia the infrarenal abdominal aorta, respectively, in the three groups. At 1, 6, 12 days after injection, Basso-Beattie-Bresnahan scores were recorded and western blot assay was used to detect hypoxia-inducible factor-1α protein expression in the spinal cord. The motor-evoked potential was determined at 12 days after injection. RESULTS AND CONCLUSION: Compared with the control group, the Basso-Beattie-Bresnahan scores were significantly higher (P < 0.05), the expression of hypoxia-inducible factor-1α protein in the spinal cord tissue was significantly increased (P < 0.05), the motor-evoked potential latency was shortened (P < 0.05) and the amplitude was increased (P< 0 .05) in the untransfected group and transfection group. Compared with the untransfected group, the Basso-Beattie-Bresnahan scores were significantly higher (P < 0.05), the expression of hypoxia-inducible factor-1α protein in the spinal cord tissue was significantly increased (P < 0.05), the motor-evoked potential latency was shortened (P < 0.05) and the amplitude was increased (P < 0 .05) in the transfection group. Above al, umbilical cord blood mesenchymal stem cel transplantation modified by hypoxia-inducible factor 1α has better effects on spinal cord ischemia-reperfusion injury.
RESUMEN
BACKGROUND:Stem cel therapy is superior to drug therapy for recovery of patient’s physiological mode, and cel transplantation therapy is becoming a trend. OBJECTIVE:To observe the changes in dopamine content in the stratum of Parkinson’s disease rats after transplantation of tyrosine hydroxylase-modified human umbilical cord blood mesenchymal stem cel s. METHODS:After identification by enzyme digestion, pEGFP-C2-TH plasmid was transfected into the fourth generation of human umbilical cord blood mesenchymal stem cel s by electroporation method, and then transfected cel s were injected into the right cerebral ventricle of Parkinson’s disease rats (experimental group). PBS injection was performed in the control group. Migration of dopamine in the brain tissue of rats was observed, and the content of dopamine was detected by high performance liquid chromatography. RESULTS AND CONCLUSION:At 8 weeks after cel transplantation, the cel s gradual y migrated to the ventricles;after 12 weeks, the cel s migrated to the cortex, and expressed tyrosine hydroxylase antigen. Meanwhile, the content of dopamine was significantly higher in the experimental group than the control group (P<0.05). These results reveal that the intraventricular transplantation of tyrosine hydroxylase-modified human umbilical cord blood mesenchymal stem cel s has obvious therapeutic effect on Parkinson’s disease rats.